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In vitro release testing is a useful tool for the quality control of controlled release parenteral 23 
formulations, but in vitro release test conditions that reflect or are able to predict the in vivo 24 
performance are advantageous. Therefore, it is important to investigate the factors that could 25 
affect drug release from formulations and relate them to in vivo performance. In this study the 26 
effect of media composition including albumin presence, type of buffer and hydrodynamics on 27 
drug release were evaluated on a liposomal Amphotericin B formulation (Ambisome®). A 28 
physiologically based pharmacokinetic (PBPK) model was developed using plasma 29 
concentration profiles from healthy subjects, in order to investigate the impact of each variable 30 
from the in vitro release tests on the prediction of the in vivo performance. It was found that 31 
albumin presence was the most important factor for the release of Amphotericin B from 32 
Ambisome®; both hydrodynamics setups, coupled with the PBPK model, had comparable 33 
predictive ability for simulating in vivo plasma concentration profiles. The PBPK model was 34 
extrapolated to a hypothetical hypoalbuminaemic population and the Amphotericin B plasma 35 
concentration and its activity against fungal cells were simulated. Selected in vitro release tests 36 
for these controlled release parenteral formulations were able to predict the in vivo AmB 37 
exposure, and this PBPK driven approach to release test development could benefit 38 
development of such formulations.  39 
 40 
Keywords: 41 
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1. Introduction 45 
A recent consensus document arising from a workshop dedicated to bringing consistency to 46 
terminology used in dissolution testing has defined a clinically relevant in vitro release test as 47 
the implication of a link between the in vitro release and the in vivo performance [1]. In order 48 
to establish a clinically relevant test, it is important to understand how the test conditions (e.g. 49 
media composition and hydrodynamics) affect the in vitro release from the formulation. In 50 
some cases, the information obtained from the in vitro release tests is not enough to explain the 51 
in vivo behaviour of the formulation and the released drug, and a mechanistic understanding of 52 
the in vivo performance is required [2]. This can be achieved by the use of physiologically 53 
based pharmacokinetic (PBPK) modeling. The general concept of PBPK modeling is to 54 
mathematically describe relevant physiological, physicochemical, and biochemical processes 55 
that determine the pharmacokinetic behaviour of a compound [3-5]. PBPK modeling and 56 
simulation are currently a trending tendency and commercial software are available (for 57 
example, Gastro- Plus®, simCYP® or PK-Sim® [6]). PBPK modeling is now accepted by 58 
regulatory agencies [7]. The Food and Drug Administration (FDA) have published the 59 
“Physiologically Based Pharmacokinetic Analyses — Format and Content (Guidance for 60 
Industry) [8]” and the European Medicines Agency (EMA) the “Guideline on the qualification 61 
and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation 62 
[9]”. A PBPK model can be developed considering 4 stages: i) setting the model equations to 63 
represent the system, ii) input data to the model, iii) perform the simulation and iv) model 64 
validation (observed vs simulated data, parameter sensitivity analysis) [2]. A sensitivity 65 
analysis allows the identification of the parameters that have the greatest influence on the 66 
simulation [10, 11].  67 
A biopredictive release method consists of in vitro release testing conditions that, coupled with 68 
mathematical modeling, are capable of predicting in vivo pharmacokinetic profiles [1]. PBPK 69 
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modeling can be extrapolated to simulate diseased populations, and could thus be used for 70 
example for hypoalbuminaemic patients (plasma albumin < 25 g/L [12]), in order to investigate 71 
the pharmacodynamics (PD) of the drug [13]. Hypoalbuminaemia can be observed in critically 72 
ill patients with sepsis, who may be among the patient cohort administered AmB.  73 
PBPK/PD models integrate the movement of the drug in the body with its pharmacological 74 
activity [13]. In antimicrobial therapy, the pharmacological effect is the activity against an 75 
infectious agent [14-16]. If a PBPK/PD model is used to evaluate the antimicrobial activity, for 76 
many antimicrobial agents the microbial killing is considered to be dependent on the PK profile 77 
of antimicrobial concentration in plasma [10, 17]. Amphotericin B (AmB) is a poorly soluble 78 
highly protein bound drug used in the treatment of severe systemic fungal disease (e.g. Candida 79 
sp., Aspergillus sp. [18, 19]) and is commercially available as parenteral lipid formulations 80 
(including the liposomal formulation Ambisome®) for intravenous administration. The 81 
development of PBPK models for Amphotericin B in mice and rats after the administration of 82 
Fungizone® (colloidal AmB) and Ambisome® have been reported [20, 21], which showed good 83 
predictive performance after being extrapolated to humans. For PBPK modeling of 84 
Ambisome®, the uptake of particles by macrophage cells in organs like the liver and spleen, 85 
were taken into account by using a saturable model. When this model was developed, the 86 
authors reported that there was no in vitro AmB release data available and they determined a 87 
value from fitting the model to the data with a release rate constant of 0.0035 h-1 (in all the 88 
tissues) with an initial rapid release of the 8% of the dose in humans [20, 21].  89 
The aims of this study were i) to investigate how the presence of albumin in clinically relevant 90 
media containing physiological surfactants (bile salts – phospholipids) [22]) combined with a 91 
biorelevant hydrodynamic environment [23], impacts on the release of AmB from Ambisome®; 92 
ii) to develop a PBPK model to predict plasma drug concentrations in healthy subjects; iii) 93 
coupled with the use of the PBPK model, to guide the development of a biopredictive in vitro 94 
5 
 
release test for the liposomal AmB formulation Ambisome®; iv) to extrapolate the PBPK model 95 
to a hypoalbuminaemic population to build a PBPK/PD model to simulate the pharmacological 96 
effect of AmB on fungal cells present in hypoalbuminaemic plasma vs plasma with normal 97 
albumin levels.  98 
2. Materials and Methods 99 
2.1. Materials 100 
AmB analytical standard (87.8%), methanol (MeOH) high performance liquid chromatography 101 
(HPLC) grade, formic acid mass spectrometry grade, Sabouraud dextrose (SBD) broth, NaOH, 102 
MgCl2, CaCl2, and NaHCO3 were obtained from Sigma Aldrich (Germany); AmB API powder 103 
(85%) from Cayman Chemical (USA); bovine serum albumin protease free powder fraction V 104 
(BSA), dimethyl sulfoxide (DMSO), dextrose, sodium dodecyl sulphate (SLS), Na2HPO4, 105 
NaH2PO4, KH2PO4, NaCl and KCl from Fisher Scientific (USA); phosphatidylcholine (PL) 106 
from egg from Lipoid GmbH (Ludwigshafen, Germany); sodium taurocholate (BS) from 107 
Prodotti Chimici e Alimentaria (Italy); Sabouraud dextrose (SBD) agar was obtained from 108 
Oxoid (UK), 25 mL sterile universal culture tubes were obtained from Sterilin Thermo 109 
Scientific (UK); 10 μL plastic loops from Microspec (UK); GF/D (pore size 2.7 μm, 25 mm 110 
diameter) and GF/F (pore size 0.7 μm, 25 mm diameter) filters from Whatman (UK); 111 
regenerated cellulose (RC) filters 0.45 µm 13 mm diameter from Cronus (UK); cellulose ester 112 
dialysis tubing of 300 kDa MWCO from Spectrum Labs (USA), C18 Sep – Pak® Vac 3cc (500 113 
mg) solid phase extraction (SPE) column from Waters (USA) and Ambisome® liposomal AmB 114 
formulation from Gilead (Gilead, UK). 115 
2.2. Sample treatment of AmB in release media 116 
The sample treatment of AmB was described previously [23]. Briefly, the SPE method to 117 
separate "liposomal AmB" (AmB still entrapped in the liposome) from "released AmB" (AmB 118 
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released from the liposome) was modified from Egger et al [24]. The SPE column was 119 
conditioned with methanol, followed by water. 1.0 mL of sample was passed through the 120 
column and the eluate was collected in a clean vial (liposomal AmB), the column was washed 121 
with 2.0 mL of water and collected in the same tube. 1.0 mL of methanol was flushed through 122 
the column to elute the AmB retained in the column (released AmB). In the case of samples 123 
with proteins, proteins were precipitated by adding 2 volumes of methanol to 1 volume of the 124 
sample followed by mixing in a vortex mixer, then centrifuged for 10 minutes at 12000 rpm 125 
and 5°C. The supernatant was filtered through a 0.45 μm RC filter before injection to the 126 
HPLC. 127 
2.3. Chromatographic conditions for the analysis of AmB from release media 128 
The chromatographic method to quantify AmB was described previously [25]. Briefly, AmB 129 
was quantified by HPLC analysis using a Hewlett Packard Series 1100 equipped with an auto 130 
sampler, temperature regulated column compartment, quaternary pump and diode array 131 
detector (DAD detector) (Agilent Technologies). The column was a C18 Waters Sunfire 132 
Column (Ireland) 150 x 46 mm 5 μm. The temperature of the column compartment was set at 133 
25°C. The mobile phase consisted of formate buffer 50 mM pH = 3.2: MeOH (27.5:72.5, v/v); 134 
the flow rate was 1 mL/min and analysis was performed with the DAD detector at λ = 406 nm. 135 
The UV spectrum was recorded from 300 to 450 nm. Quantification of AmB in samples was 136 
made based on calibration curves. Freshly prepared standard solutions (0.5 – 15 μg/mL) in the 137 
corresponding medium were prepared by appropriate dilution of a 500 μg/mL stock solution 138 
of AmB analytical standard in 1:1 MeOH: DMSO v/v. The limit of detection and the limit of 139 
quantification were 0.12 and 0.37 μg/mL, respectively.  140 
2.4. In vitro release studies of AmB from Ambisome®  141 
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The factors investigated for the development of the in vitro release studies were: i. the 142 
composition of the clinically relevant media with biorelevant surfactants (media AmB 143 
solubility value equivalent to that observed in plasma from healthy subjects [22]); media 144 
composition factors explored were: type of buffer and BSA concentration, and ii. the 145 
hydrodynamic conditions in terms of the apparatus used i.e. sample and separate (bottle/stirrer) 146 
or continuous flow (flow through cell apparatus).  147 
Media compositions were PBS BS 19.8 mM PL 7.9 mM and KRB BS 20.0 mM PL 4.0 mM, 148 
with and without BSA 4.0% w/v. Media preparation was as previously described [22]. Briefly, 149 
BS were weighed and dissolved in buffer and then PL from a stock solution of 100 mg/mL in 150 
dichloromethane was added. Organic solvents were evaporated with a rotary evaporator set at 151 
40°C and attached to a vacuum pump. The pressure was decreased from 650 mbar by steps of 152 
70 mbar every two minutes to 100 mbar, where the pressure was maintained for 10 minutes. 153 
When included in the medium, BSA was added after the evaporation of the organic solvents. 154 
2.4.1. Sample and separate method (bottle/stirrer setup) 155 
The sample and separate method was described previously [23]. Briefly, Ambisome® powder 156 
(0.5 mg AmB) was placed into a 100 mL glass bottle with 30 mL of release medium and stirred 157 
with a magnetic stirrer at 37°C. Release studies were performed based on a two-level factorial 158 
design of experiments (DoE). The factors investigated (composition of release media and 159 
agitation conditions) are shown in Table 1; the combination of all the factors resulted in eight 160 
experimental setups.  161 
The agitation rates in the bottle/stirrer setup were selected based on the linear velocity of the 162 
stirrer edge, which at 130 rpm (10.2 cm/s) is comparable to the linear flow velocities in 163 
vein/arteries and at 380 rpm (29.5 cm/s) to flow velocities in the aorta [23]. Sampling times 164 
were 1, 2, 4, 6, 8, and 12 h and after sample treatment (SPE and protein precipitation), samples 165 
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were injected to the HPLC and AmB concentration in the samples was determined. All 166 
experiments were performed in triplicate.  167 
2.4.2. Continuous flow (flow through cell apparatus) 168 
The flow-through apparatus setup was described previously [23]. Briefly, AmB release studies 169 
were carried out in a flow-through dissolution apparatus (Sotax CE7 smart connected to a Sotax 170 
piston pump CP7, Sotax, Aesch Switzerland) operated in the closed mode [26]. A 5 mm ruby 171 
glass bead was positioned at the bottom of the cell (large cell: 22.6 mm diameter). The dialysis 172 
membrane was placed into the flow through cell apparatus dialysis adapter and Ambisome® 173 
powder (0.5 mg AmB) was placed into the membrane with 1 mL of the release medium. Glass 174 
fibre filters (GF/D, GF/F) were positioned at the top of the cell. The release studies were based 175 
on a two level factorial DoE, where the velocities used were considered biorelevant: “Low 176 
velocity” (flow rate: 8 mL/min) has an average linear velocity comparable to capillary flow 177 
and “High velocity” (flow rate: 35 mL/min) is comparable to intermediate capillary-vein flow 178 
[23] and BSA presence (4.0% w/v) or not were the factors investigated. 36 mL of KRB BS 179 
20.0 mM PL 4.0 mM (with or without BSA) were used in order to simulate the equivalent 180 
volume available on administration of 1 mg/kg of AmB as Amphotericin B® to a 70 kg subject 181 
(assuming 5 L of blood volume). Furthermore, as the 36 mL volume used does not allow for 182 
distribution as would happen in vivo, it represents an extreme case in terms of available volume. 183 
 184 
2.5. Release data treatment 185 
The release data treatment was described previously [23]. Briefly, for the studies with the 186 
sample and separate method, % AmB released over time was calculated based on the % AmB 187 
still entrapped in the liposomes at the time of sampling (%𝐴𝑚𝐵𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙) (Eq 1) to construct 188 
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the calculated %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 profile. %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑖𝑛𝑖𝑡𝑖𝑎𝑙 − %𝐴𝑚𝐵𝑙𝑖𝑝𝑜𝑠𝑜𝑚𝑎𝑙 189 
  (Eq 1)  190 
where %𝐴𝑚𝐵𝑖𝑛𝑖𝑡𝑖𝑎𝑙 is the mass of AmB placed into the reservoir initially (100%) and 191 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 is the calculated AmB percent released.  192 
For the studies with the continuous flow setup the %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) over time was corrected 193 
for degradation using Eq 2 to construct the calculated %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 profile. 194 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 =  %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) + 𝑘𝑑𝑒𝑔 ∗ 𝐴𝑈𝐶0−𝑡  (Eq 2)  195 
where %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 is the corrected % AmB released accounting for degradation, 196 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑(𝑜𝑏𝑠) is the % AmB released at time t, 𝐴𝑈𝐶0−𝑡 is the Area Under the Curve of 197 
the observed concentration – time curve from time 0 to time 𝑡 and 𝑘𝑑𝑒𝑔 is the degradation rate 198 
constant obtained from the degradation experiments [22]. 199 
The AmB release rate constant (𝑘𝑟𝑒𝑙) from Ambisome
® was obtained from first order fitting 200 
of calculated %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 individual profiles (Equation 3) and mean and standard deviation 201 
values were calculated (GraphPad Prism 7, GraphPad Software, Inc, USA). 202 
%𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 = %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 ∗ (1 − 𝑒
−𝑘𝑟𝑒𝑙𝑡) (Equation 3),  203 
where %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 is the maximum AmB percent released and 𝑡 is time. 204 
2.6. Atomic Force Microscopy (AFM) studies 205 
To further investigate the effect of the clinically relevant media components (e.g. BS, PL and 206 
BSA) on the liposomes, AFM studies were performed. The AFM methodology has been 207 
described previously [23]. Ambisome® liposomes were incubated in KRB BS 20.0 mM PL 4.0 208 
mM BSA 4.0% w/v (for 30 min) and in KRB BS 20.0mM PL 4.0 mM (for 5 min; a shorter 209 
period of incubation was set in order to reflect the fast release of AmB from the liposomes 210 
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observed in the absence of BSA). After the incubation time, samples were centrifuged for 30 211 
min at 13,300 rpm in an Eppendorf centrifuge, the supernatant was discarded and the pellet 212 
was dried under vacuum. The pellets were diluted with 1 mL of HPLC water, and then 10 µL 213 
of the liposomal solution was placed on a freshly cleaved mica surface (1.5 cm × 1.5 cm; G250-214 
2 Mica sheets 1″ × 1″ × 0.006″; Agar Scientific Ltd., Essex, UK). The sample was then air-215 
dried for ∼30 min and imaged immediately by scanning the mica surface in air under ambient 216 
conditions using a Bruker MultiMode 8 Scanning Probe Microscope (Bruker, Billerica, 217 
Massachusetts, USA) operated on Peak Force QNM mode. The AFM measurements were 218 
obtained using ScanAsyst-air probes (Bruker, Billerica, Massachusetts, US); the spring 219 
constant was calibrated by thermal tune (Nominal 0.4 N m−1) and the deflection sensitivity 220 
calibrated using a silica wafer. AFM scans were acquired at a resolution of 512 × 512 pixels at 221 
scan rate of 1 Hz, and produced topographic images of the samples in which the brightness of 222 
features increases as a function of height. The raw image data were processed using Bruker 223 
Nanoscope Analysis (version 1.5), and height images were flattened to remove sample tilt and 224 
scanner bow. The surface roughness (Ra) of each substrate was determined by using Nanoscope 225 
Analysis’ algorithm to analyse several scans of the surface from different locations (n = 20). 226 
AFM images were collected from random spot surface sampling (at least four areas).  227 
2.7. PBPK modeling for Ambisome® administration to healthy subjects 228 
2.7.1 Data for PBPK modeling.  229 
Published data of plasma concentration profiles from a population of 5 healthy subjects (4 230 
males, 1 female; ages from 33 to 65 years; height from 1.61 to 1.68 m; and weight from 68 to 231 
86 kg) administered 2.0 mg/kg of Ambisome® by intravenous infusion over 2 h where the 232 
"liposomal AmB" and "released AmB" were quantified [27, 28], were digitalized with Webplot 233 
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digitalizer 3.8 software. "Liposomal AmB" and "released AmB" distribution, clearance, protein 234 
binding and physicochemical properties are shown in Table 2. 235 
The PK parameters (distribution, clearance and protein binding) for "released AmB" were as 236 
reported by Kagan et al. after administration of the colloidal AmB formulation Fungizone® 237 
[21] (Table 2). Protein binding was characterized by kdiss (equilibrium dissociation constant). 238 
The nominal glomerular filtration rate (GFR) for AmB was 0.08 mL/min/kg as calculated using 239 
Eq 4, based on a fraction unbound of 0.05. This value was used to calculate the GFR fraction 240 
for the "liposomal AmB" and "released AmB". 241 
𝑁𝑜𝑚𝑖𝑚𝑎𝑙 𝐺𝐹𝑅 =  𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑢𝑛𝑏𝑜𝑢𝑛𝑑 (𝑎𝑙𝑏𝑢𝑚𝑖𝑛) ∗ (120 𝑚𝐿/𝑚𝑖𝑛) ∗ (1/73 𝑘𝑔) Eq 242 
4. 243 
The biliary elimination rate constant was calculated using Eq 5. 244 
𝑘𝑏𝑖𝑙 = (𝐶𝑙𝑏𝑖𝑙𝑖𝑎𝑟𝑦/𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑢𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒)(60 𝑚𝑖𝑛/1 ℎ) Eq 5. 245 
For the development of the model, "liposomal AmB" was assumed to behave as a molecule as 246 
the concentration of AmB is what is quantified in the in vivo studies and not the concentration 247 
or amount of liposomes. 248 
An "immune" enzyme was added for the "liposomal AmB" to account for the removal of 249 
circulation of the "liposomal AmB" by the macrophages of the immune system. The enzyme 250 
was set to be located in the plasma, liver and spleen. The fraction unbound value for the 251 
"liposomal AmB" was hypothesized to be smaller than 0.95 based on the reported interaction 252 
between albumin and liposomes [38-40]. All the other parameters were left as software default 253 
values.  254 
2.7.2. Workflow for PBPK modeling of Ambisome®  255 
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The workflow for the PBPK modeling to describe the pharmacokinetics of "liposomal AmB" 256 
and "released AmB" in a healthy individual after the administration of the Ambisome® is 257 
presented in Figure 1.  258 
PBPK modeling was performed with PKSim® 7.2.1 (Bayer, Germany) and MoBi® 7.2 (Bayer, 259 
Germany). The five parameters listed in Figure 1 were optimized simultaneously with the 260 
MoBi® built in function "Parameter identification" using an algorithm based on Monte Carlo 261 
methods and the default software setup (the Parameter identification tool varies selected input 262 
parameters in a given range to identify the best values to obtain output simulated curves similar 263 
to the observed curves). The in vivo release of AmB from the liposomes was set to occur only 264 
in plasma (𝑘𝑟𝑒𝑙−𝑖𝑣). 265 
Comparing the developed PBPK model in this study with that reported by Kagan et al [21], 266 
there were some differences: i) this model was developed in order to link the in vitro release 267 
data to the observed plasma concentration data while Kagan and co-workers developed their 268 
model to have a better understanding of AmB PK in order to improve dosing; ii) the model 269 
developed by Kagan et al. assumed that release of AmB took place in all compartments [21] 270 
while in this study, the release was modelled in plasma only. 271 
Sensitivity analysis was performed on all the parameters of the model (PK parameter estimates 272 
and physicochemical properties of "liposomal AmB" and "released AmB") except for the 273 
molecular weight and the pKa values of "released AmB". The parameters and the range in 274 
which the sensitivity analysis was evaluated are presented in Table 3.  275 
The ranges were selected as follows: logP of "liposomal AmB" and "released AmB": ± 1 log 276 
unit of the optimized value, immune enzyme of "liposomal AmB": ± 1 h–1 of the optimized 277 
value, aqueous solubility of "released AmB": the range was selected to cover the solubility 278 
values reported in the literature [33-35], aqueous solubility of "liposomal AmB": ± 200 µg/mL 279 
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in order to cover a wide range as the solubility value was calculated by considering the total 280 
amount of formulation powder in a vial (14.5 g), dissolved in 50 mL of water (Table 2); for 281 
radius solute ("liposomal AmB"), biliary clearance ("liposomal AmB" and "released AmB"), 282 
𝑘𝑑𝑖𝑠𝑠 of lipoprotein B (APOB) and alpha1-acid glycoprotein (AAG1) the interval was ± 50% 283 
of the literature value (Table 2 and 3). The GFR fraction ("liposomal AmB" and "released 284 
AmB") was investigated ranging from 0 to 1; and the unbound to protein fraction ("liposomal 285 
AmB" and "released AmB") from 0.05 to 0.95. 𝑘𝑟𝑒𝑙−𝑖𝑣 was investigated in the interval of the 286 
𝑘𝑟𝑒𝑙 found in the in vitro tests (Table 3). 𝐴𝑈𝐶0−24ℎ of both liposomal and released AmB was 287 
used as response to evaluate the effect of the parameters investigated. Sensitivity analysis was 288 
performed with the MoBi Toolbox for R esqLABS version 7.2.1 (esq LABS, Germany). All 289 
the intervals tested, were normalized to 0 – 1 for clarity of presentation. 290 
After the sensitivity analysis, the model was applied to the population described in section 291 
2.7.1. The variability (standard deviation) for the parameters input into the model was as 292 
described in Table 2. As the values of 𝑘𝑟𝑒𝑙−𝑖𝑣 and specific clearance for the immune removal 293 
"enzyme" were obtained by parameter identification and there are no reported values for their 294 
variability, 20% of the identified value was used as standard deviation. 295 
2.7.3. Evaluation of the in vitro tests using PBPK modeling 296 
The in vitro 𝑘𝑟𝑒𝑙 (Mean ± SD) obtained from the in vitro release profiles of AmB from 297 
Ambisome® were input to the validated PBPK model in order to predict the observed in vivo 298 
AmB ("liposomal AmB" and "released AmB") plasma concentration profiles. The 𝐴𝑈𝐶0−24ℎ 299 
was calculated from the predicted "liposomal AmB" and "released AmB" plasma concentration 300 
profiles. 301 
2.8. PBPK-PD model for the pharmacological activity of AmB against Candida albicans 302 
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The effect of AmB on Candida albicans (C. albicans) was investigated in order to develop a 303 
PBPK-PD model: i. for a patient population receiving Ambisome® with a reduced albumin 304 
plasma concentration (hypalbuminaemia: albumin < 25 mg/mL), and ii. for a healthy 305 
population receiving Ambisome® with normal concentration of albumin (~4.0% w/v). 306 
2.8.1. Quantification of C. albicans 307 
The culture and quantification of C. albicans was described previously [25]. A single colony 308 
culture was started in a tube with 5 mL of SBD broth and incubated overnight at 37°C in a 309 
shaking incubator; the optical density was measured at 600 nm (OD600). The colony forming 310 
units (CFU) were determined by preparing serial dilutions and the suspensions were plated on 311 
SBD agar plates, incubated overnight at 37°C and the number of colonies were counted and 312 
related to the OD600 of the culture. 313 
2.8.2. Time killing experiments 314 
Time killing experiments were performed with 105 CFU/mL of C. albicans using different 315 
AmB final concentrations (0.00, 0.75, 1.50 and 3.00 µg/mL) in the presence of BSA 2.0% and 316 
4.0% w/v in KRB [an experiment without AmB was performed in order to obtain the 𝑘𝑔𝑟𝑜𝑤𝑡ℎ  317 
of the fungal cells]. The % CFUs remaining at each time point were used for curve fitting to 318 
the exponential decay equation to obtain the killing rate coefficient for each concentration 319 
tested (Eq 6).  320 
%𝐶𝐹𝑈 = %𝐶𝐹𝑈𝑚𝑎𝑥 ∗ 𝑒
−𝑘𝑘𝑖𝑙𝑙𝑡 Eq 6. 321 
where %𝐶𝐹𝑈 is the %CFU at time t, %𝐶𝐹𝑈𝑚𝑎𝑥 is the maximum %CFU, 𝑘𝑘𝑖𝑙𝑙 is the time killing 322 
rate coefficient and 𝑡 is time.  323 
A linear relation was found between 𝑘𝑘𝑖𝑙𝑙 and AmB concentration and it was used in the PBPK-324 
PD model. 325 
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2.8.3 PBPK-PD modeling 326 
The workflow for the development of the PBPK-PD model is shown in Figure 2. 327 
To simulate a hypoalbuminaemic patient population, the protein content was halved in the 328 
validated PBPK model for the healthy subjects and the rest of the parameters remained 329 
unchanged. The "released AmB" concentration was used to calculate the 𝑘𝑘𝑖𝑙𝑙 for the 24 h time 330 
course to simulate the "released AmB" activity against C. albicans which was set at a 331 
concentration of 105 CFU/mL at time zero. The C. albicans growth rate constant (𝑘𝑔𝑟𝑜𝑤𝑡ℎ) was 332 
obtained from the control time killing experiment (0.00 µg/mL AmB) by fitting the data to an 333 
exponential growth equation (Eq 7) 334 
%𝐶𝐹𝑈 = 𝐴𝑒𝑘𝑔𝑟𝑜𝑤𝑡ℎ𝑡 (Eq 7) 335 
where %𝐶𝐹𝑈 is the %CFU at time t, 𝐴 is the starting CFU value , 𝑘𝑔𝑟𝑜𝑤𝑡ℎ is the growth rate 336 
constant and 𝑡 is time. 337 
2.9. Statistical analysis 338 
The statistical analysis was described previously [23]. Pareto charts, based on the DoE analysis, 339 
were performed for the identification of significant effects from the in vitro release tests. A 340 
factor was significant when the standardized effect (bars) was larger than the line for statistical 341 
significance level (α = 0.05) (vertical line). An independent means t – test was performed to 342 
compare 2 independent means: in the AFM studies, size and surface roughness were compared 343 
against the control sample. A p<0.05 was considered statistically significant. Due to the lack 344 
of individual observed data of plasma concentration profiles, the in vitro 𝑘𝑟𝑒𝑙 were input into 345 
the PBPK model to obtain simulated 𝐴𝑈𝐶0−24ℎ which were compared against the 𝐴𝑈𝐶0−24ℎ 346 
obtained from the simulated data generated by the validated PBPK model. 347 
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Additionally, the 90% confidence interval (90% CI) for the ratio of the geometric means of the 348 
simulated 𝐴𝑈𝐶0−24ℎ obtained with the in vitro 𝑘𝑟𝑒𝑙 and the 𝐴𝑈𝐶0−24ℎ obtained from the 349 
simulated data generated by the validated PBPK model were calculated. As recommended by 350 
the FDA guidance, both "liposomal AmB" and "released AmB" were evaluated [39]. Data 351 
analysis, creation and analysis of DoE were performed with the statistical software Statgraphics 352 
Centurion XVII (USA) and the 90% CI were calculated with IBM SPSS Statistics 25 (USA).  353 
3. Results and discussion 354 
3.1. In vitro release testing of Ambisome®  355 
In vitro release profiles of AmB from Ambisome® in both hydrodynamic setups are shown in 356 
Figure 3 and parameters obtained after fitting to the first order equation model are presented in 357 
Table 4. 358 
For the sample and separate setup, the statistical analysis (Figure 4a) showed that the buffer 359 
was a significant factor affecting %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 with a higher release in KRB, the 360 
presence of BSA 4.0% w/v had a significant negative effect. The interaction between buffer 361 
and BSA was significant as the amount released in KRB with BSA is slightly higher than in 362 
PBS with BSA, while in media without BSA there is no difference. The release rate constant 363 
was affected in the same way as %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 but the interaction between buffer and 364 
BSA showed that the release rate is faster in KRB than in PBS without BSA and there is not a 365 
statistical significant difference in KRB and PBS with BSA. For the continuous flow setup 366 
(Figure 4b), the flow rate was the only significant factor affecting AmB release from the 367 
liposomes, with a positive effect on the 𝐴𝑈𝐶0−12ℎ. 368 
3.2. AFM studies 369 
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Figure 5 shows the images obtained from the AFM and Table 5 contains the parameters of the 370 
liposome characteristics measured by AFM.  371 
Diameter of the liposomal structures in samples from KRB BS 20.0 mM PL 4.0 mM are 372 
significantly higher than the control sample; liposomes could be merging with each other or 373 
the inclusion of BS PL could alter the structure of the liposome resulting in a higher size before 374 
the disruption. Liposomes were not visible in the sample of from KRB BS 20.0 mM PL 4.0 375 
mM BSA 4.0% w/v, probably due to the incubation period of this sample. 376 
3.3. PBPK modeling of Ambisome® administered to healthy subjects 377 
The simulated plasma concentration profiles obtained with the validated PBPK model for the 378 
administration of Ambisome® to healthy subjects are shown in Figure 6.  379 
Using the parameter identification method, the optimal values for the parameters investigated 380 
were: 𝑘𝑟𝑒𝑙−𝑖𝑣 = 0.60 h
-1, logP (released AmB) = 3.24, logP (liposomal AmB) = 1.0, Specific 381 
clearance for the immune removal "enzyme" = 2.57 h-1 and AAG1 𝑘𝑑𝑖𝑠𝑠 = 0.42 µmol/L. The 382 
logP and clogP values reported in the literature, are between -2.33 to 2.14 (Table 2) providing 383 
a wide interval for the true value. The value obtained from parameter identification fitting was 384 
3.24 which could be supported considering the distribution of the values previously reported 385 
(Table 2). 386 
The PBPK model described closely the average observed data for "liposomal AmB" and 387 
"released AmB" (%.𝐴𝑈𝐶0−24ℎ predicted/𝐴𝑈𝐶0−24ℎ observed were 94% and 101%, 388 
respectively). Comparing the developed PBPK model in this study with the one reported by 389 
Kagan et al [21], the main difference was the 𝑘𝑟𝑒𝑙−𝑖𝑣 from this model was faster: 0.60 h
-1 > 390 
0.0035 h-1 [21] and there was no initial rapid release of 8.0% of the dose, as was included by 391 
Kagan et al [21]. It could be due to simulated AmB release taking place in all of the 392 
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compartments in the model presented by Kagan et al. [21], while in this study; the release was 393 
only in plasma. 394 
The sensitivity analysis is shown in Figure 7. Parameters such as aqueous solubility ("liposomal 395 
AmB" and "released AmB"), solute radius ("liposomal AmB"), specific biliary clearance 396 
("liposomal AmB" and "released AmB"), 𝑘𝑑𝑖𝑠𝑠 for AAG1 and APOB ("released AmB"), and 397 
the GFR for "released AmB" did not have a significant impact on the 𝐴𝑈𝐶0−24ℎ of "liposomal 398 
AmB" or "released AmB". For the "liposomal AmB", the fraction unbound to proteins had the 399 
greatest impact on the model. It can be observed how the "liposomal AmB" in plasma decreases 400 
as the fraction unbound increases, leading to a decrease in "released AmB", as there will be 401 
less "liposomal AmB" available in plasma to release drug. 𝑘𝑟𝑒𝑙−𝑖𝑣 had a high impact on both 402 
"liposomal AmB" and "released AmB" (Figure 7), with a higher release rate constant leading 403 
to an increase in the "released AmB" and a decrease in the "liposomal AmB". For "released 404 
AmB", logP is the factor with the highest effect on  𝐴𝑈𝐶0−24ℎ. 405 
3.4. Evaluation of the in vitro release profiles using the PBPK model 406 
The predictability of the in vitro release tests is presented in Figure 8 for both "liposomal AmB" 407 
and "released AmB". 408 
For the "liposomal AmB", the 𝐴𝑈𝐶0−24ℎ obtained with the in vitro 𝑘𝑟𝑒𝑙 where BSA was present 409 
in the media were similar to the 𝐴𝑈𝐶0−24ℎ obtained from the validated PBPK model, regardless 410 
of the type of the buffer or the hydrodynamic conditions. The 𝐴𝑈𝐶0−24ℎ values were only 411 
similar for a medium without BSA in the low velocity setup (Figure 8). For the "released 412 
AmB", the 𝐴𝑈𝐶0−24ℎ obtained with the in vitro 𝑘𝑟𝑒𝑙 in media with BSA were close to attaining 413 
similarity to the in vivo profiles, as all the tests (except KRB BS PL BSA low agitation) 414 
revealed one extreme of the 90% CI between 80 – 125%. It can be noticed that the tests 415 
performed with the continuous flow setup under-predicted the plasma concentration of the 416 
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"released AmB". An increasing flow rate leads to a higher drug release (Figure 4) thus further 417 
exploration of flow rate effect could be conducted to identify the flow rate resulting in release 418 
profiles suitable for simulation of in vivo release. The 𝐴𝑈𝐶0−24ℎ could not be calculated for 419 
the high velocity profiles as for the medium without BSA the standard deviation was higher 420 
than the mean and for the medium with BSA the profiles could not be fitted to the first order 421 
equation. The model developed is suitable for the evaluation of the in vitro release tests and 422 
could support the development of a biopredictive in vitro release test. It has to be noted that for 423 
the prediction of the plasma concentration of "liposomal AmB" and "released AmB", the 424 
presence of BSA was a critical factor, thus, information on the exact mechanism of the protein 425 
binding to the liposomes could further improve the model developed. Furthermore, the 426 
accuracy of model could be further improved through inclusion of parameters capturing AmB 427 
binding to red blood cells, as in general only plasma concentrations are presented in the 428 
literature while the formulation is obviously administered to the venous blood pool. 429 
3.5. PBPK – PD modeling for the patient (hypoalbuminaemic) population. 430 
Parameters obtained after fitting to the exponential decay equation model for the time killing 431 
experiments are presented in Table 6. A linear relationship between the AmB concentration 432 
and the time killing rate coefficient was found for experiments with BSA 2.0 and 4.0% w/v, 433 
(Eq 8 and eq. 9, respectively)  434 
𝑡𝑖𝑚𝑒 𝑘𝑖𝑙𝑙𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (ℎ−1) = 0.1923(𝑚𝐿 ∗ ℎ−1) ⁄ 𝜇𝑔 + 0.2102 ℎ−1  Eq 8. 435 
𝑡𝑖𝑚𝑒 𝑘𝑖𝑙𝑙𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (ℎ−1) = 0.1167 (𝑚𝐿 ∗ ℎ−1) ⁄ 𝜇𝑔 + 0.014 ℎ−1  Eq 9. 436 
The simulated plasma concentration profiles for "liposomal AmB" and "released AmB" in the 437 
extrapolated hypoalbuminaemic population and the healthy subject population are presented in 438 
Figure 9a. It can be observed that both "liposomal AmB" and "released AmB" are at a lower 439 
concentration as a consequence of the decrease of the amount of proteins present. There is a 440 
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lower concentration as with more unbound drug there is more drug available for distribution 441 
and clearance. Figure 9b shows the simulated plasma concentration profiles for a typical 442 
administration of Ambisome® to a patient with a systemic fungal infection (300 mg, infusion 443 
4 h) in the simulated hypoalbumanaemic patient and in a subject with normal albumin levels.  444 
Equations 8 and 9 were used in the PBPK-PD model to simulate the killing of C. albicans 445 
(Figure 9c).It can be observed how the growth of the fungal cells is reduced by the 446 
administration of Ambisome® (Figure 9d) with a higher effect in the simulated 447 
hypoalbuminaemic patient than in the subject with normal albumin levels. From the time 448 
killing studies and previous data on minimum inhibitory and fungicidal concentrations [25], a 449 
higher fungicidal effect is reached with a lower AmB concentration in the presence of BSA 450 
2.0% w/v as there is more unbound drug able to exert its pharmacological effect. It has to be 451 
noted that only the effect of released AmB is evaluated in this PBPK-PD model. The humoral 452 
and cellular immune responses and the effect that the liposomal AmB could have on C. 453 
albicans are not considered, nor is the effect of fungal phospholipases on liposomal integrity 454 
and AmB release. A number of 105 CFU/mL were used to simulate the effect of AmB in vivo 455 
as this was the concentration of the fungal cell suspensions used in the time killing experiments. 456 
It has been reported that a concentration of 100 – 1000 CFU/mL are found in cultures of blood 457 
from patients with systemic fungal infection [41, 42]. The PBPK-PD analysis could be further 458 
improved by using the adequate number of CFU quantified in plasma from infected patients to 459 
evaluate the response of the humoral immune response and not only the effect of the protein 460 
content. In plasma from healthy subjects the fungal cells did not grow (data not shown), thus, 461 
the results of the PBPK-PD model for the healthy subject must be only considered as an 462 
exercise for comparative purposes. For this model, only the changes in the albumin levels were 463 
considered, leaving aside the physiological characteristics of septic or critically ill patients. In 464 
order to improve the model, the change in the activity of the immune enzyme should be 465 
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adjusted to the patient population as the immune system might be compromised or activated, 466 
and the  𝑘𝑟𝑒𝑙−𝑖𝑣, which the in vitro tests showed to be dependent on the albumin concentration, 467 
should also be adjusted. This approach reveals the potential of the use of in vitro release data 468 
and suitable microbiology data in combination with a PBPK-PD model in order to guide 469 
parenteral formulation development based on pharmacodynamics and therapeutic outcomes. 470 
4. Conclusions 471 
The literature available for in vitro release testing of controlled release parenteral formulations 472 
is limited. The evaluation of factors that can affect the release from these formulations and the 473 
development of in vitro release tests that are able to predict the in vivo performance are of high 474 
importance. In this work, the development of a clinically relevant in vitro release test for the 475 
liposomal formulation of AmB (Ambisome®) was investigated. A PBPK model was developed 476 
for the administration of Ambisome® to healthy subjects, which was used to identify the critical 477 
factors for AmB release from liposomes and the in vivo predictability of the in vitro release 478 
tests. The presence of BSA in the media was the most critical factor affecting the AmB release, 479 
and the in vitro release profiles from tests with BSA in the medium were biopredictive. 480 
Successful predictions of the “liposomal AmB” and the “released AmB” plasma concentration 481 
profile were obtained with both hydrodynamic setups tested (sample and separate method and 482 
continuous flow method). A PBPK-PD model of the activity of AmB on fungal cells was 483 
developed based on the predicted "released AmB" plasma concentration profile in a 484 
hypoalbuminaemic population in order to illustrate the potential of linking in vitro release 485 
testing, PBPK modeling and microbiology data. 486 
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Table 1. Levels and factors investigated with the sample and separate setup for the release 625 
studies of AmB from Ambisome® in clinically relevant media. 626 
Level BSA %w/v Medium Agitation (rpm) 
- 1 2.0 PBS BS 19.8 mM PL 7.9 mM 130 (Low Agitation) 




Table 2. PK-Sim model set up: physicochemical properties, distribution and clearance parameters of "released AmB" and "liposomal AmB" 
(Ambisome®) after administration to healthy subjects. 
"Released AmB" 
Molecular weight (g/mol) 924 [29, 30] 
log P 0.80 [29], 0.94 [31], 1.84 [31], 2.14 [31] 
clog P - 2.33 [29], - 0.66 [29], 1.16 [32] 
pka acidic 5.5 [30], basic 10.0 [30] 
Solubility at pH = 7 0.09 µg/mL [33], 1.38 µg/mL [34], 6.00 µg/mL [35] 
fraction unbound (albumin) 0.05 [28] 
Distribution volume 2340 ± 202 mL/kg [27] 
Cl renal 0.07 ± 0.01 mL/min/kg [27]. GFR fraction = 0.875 





alfa 1 acid glycoprotein (AAG1), EST expression, kdiss = 1.07 – 2.44 μmol/L (approximation from unbound 
fraction) [27] 
beta lipoprotein (APOB), EST expression, kdiss = 0.25 μmol/L [36] 
"Liposomal AmB" 
Distribution volume 1628 ± 876 mL/kg [27] 
Cl renal 0.01 ± 0.00 mL/min/kg [27], GFR fraction = 0.125 
Cl biliary 0.01 ± 0.00 mL/min/kg [27], kbil = 0.0003 h
-1 
Assumptions for the model, considering the "liposomal AmB" as a molecule 
Molecular weight (g/mol) 924 
Radius (solute) 80 nm [37] 




Solubility at pH = 7 
290 mg/mL [calculated from the total amount of powder in a formulation vial (14.5 g), dissolved in 50 mL 
of water] 
fraction unbound albumin 0.05 
Immune removal 
Metabolizing enzymes -> Intrinsic clearance First order -> 
Relative expression -> Intracellular -> Endosomal 
Plasma    100% 
Liver periportal  100% 
Liver pericentral             100% 




Table 3. Parameters and the range in which the parameters were investigated in the sensitivity 
analysis of the validated PBPK model of Ambisome® administration. 
Parameter Abbreviation Interval tested 
log P ("liposomal AmB") logP (lip) 0 – 2 (log units) 
log P ("released AmB") logP (rel) 2.24 – 4.24 (log units) 
Aqueous solubility ("liposomal 
AmB") 
Sol (lip) 90 – 490 (μg/mL) 
Aqueous solubility ("released AmB") Sol (rel) 0.01 – 6.00 (μg/mL) 
Radius solute ("liposomal AmB") Rad (lip) 40 – 120 (nm) 
kbil ("liposomal AmB") Bil (lip) 0.0001 – 0.0005 (h
–1) 
kbil ("released AmB") Bil (rel) 0.001 – 0.003 (h
–1) 
GFR ("liposomal AmB") GFR (lip) 0 – 1 (fraction) 
GFR ("released AmB") GFR (rel) 0 – 1 (fraction) 
"Immune enzyme" specific clearance Imm 1.57 – 3.57 (h–1) 
APOB1 𝑘𝑑𝑖𝑠𝑠 APOB1 0.12 – 0.37 (μmol/L) 
AAG1 𝑘𝑑𝑖𝑠𝑠 AAG1 0.21 – 0.63 (μmol/L) 
𝑘𝑟𝑒𝑙−𝑖𝑣 krel 0.114 - 3.539 (h
–1) 
Unbound fraction ("liposomal 
AmB") 
fU (lip) 0.05 – 0.95 (fraction) 
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Table 4. Parameters obtained after fitting (Eq 3) of %AmB released profiles from Ambisome® with the sample and separate setup and the 




Surfactant concentrations Agitation/velocity 𝒌𝒓𝒆𝒍 (h
-1
) %𝑨𝒎𝑩𝒓𝒆𝒍𝒆𝒂𝒔𝒆𝒅𝒎𝒂𝒙 
Sample and separate 
PBS 0.0 BS 19.8 mM PL 7.9 mM LA 1.425 ± 0.101 96.258 ± 0.101 
PBS 4.0 BS 19.8 mM PL 7.9 mM LA 0.701 ± 0.060 78.573 ± 2.548 
KRB 0.0 BS 20.0 mM PL 4.0 mM LA 3.034 ± 0.106 99.201 ± 0.321 
KRB 4.0 BS 20.0 mM PL 4.0 mM LA 0.621 ± 0.192 81.662 ± 2.931 
PBS 0.0 BS 19.8 mM PL 7.9 mM HA 2.437 ± 0.129 98.953 ± 0.158 
PBS 4.0 BS 19.8 mM PL 7.9 mM HA 0.410 ± 0.052 73.031 ± 6.013 
KRB 0.0 BS 20.0 mM PL 4.0 mM HA 2.747 ± 0.046 99.146 ± 0.072 
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KRB 4.0 BS 20.0 mM PL 4.0 mM HA 0.896 ± 0.041 88.141 ± 2.480 
Continuous flow 
KRB 0.0 BS 20.0 mM PL 4.0 mM LV 0.305 ± 0.071 49.181 ± 17.119 
KRB 4.0 BS 20.0 mM PL 4.0 mM LV 0.467 ± 0.162 43.101 ± 10.563 
KRB 0.0 BS 20.0 mM PL 4.0 mM HV 1.364 ± 1.890 60.416 ± 4.593 




Table 5. Properties of liposomes obtained from atomic force microscopy from the samples 










KRB control (centrifugation/vacuum) 69.4 ± 18.9 12.9 ± 1.6 11.9 
KRB BS 20.0 mM PL 4.0 mM 130.0 ± 13.0 10.1 ± 2.7 7.7 




Table 6. Parameters obtained after fitting (Equation 6) of CFU time profiles from time killing 
experiments in KRB BSA 2 and 4% w/v using different concentrations of AmB (0.75, 1.5 and 






–1) R2 AIC 
2.0 
0.75 105.1 ± 5.23 0.33 ± 0.03 0.86 ± 0.02 52.88 ± 0.3 
1.50 110.65 ± 4.17 0.54 ± 0.03 0.93 ± 0.05 47.16 ± 6.17 
3.00 110.6 ± 5.37 0.77 ± 0.11 0.92 ± 0.05 48 ± 6.43 
4.0 
0.75 101.75 ± 4.6 0.11 ± 0.01 0.89 ± 0.01 47.25 ± 2.38 
1.50 123.8 ± 10.04 0.17 ± 0.03 0.84 ± 0.07 54.71 ± 5.18 





Figure 1. Workflow for the PBPK modeling of "liposomal AmB" and "released AmB" after 
the administration of Ambisome® to healthy subjects 
Figure 2. Workflow for the PBPK-PD modeling of the liposomal and released AmB after the 
administration of Ambisome® to a hypoalbuminaemic population in order to simulate the 
pharmacological activity of the released AmB on C. albicans. 
Figure 3. % AmB released with the a) sample and separate and the b) continuous flow setup 
at 37 °C to investigate the effect of the type of buffer, the BSA 4.0% w/v presence and the 
hydrodynamics in clinically relevant media with BS – PL. (Mean ± SD, n=3; solid lines: media 
with BSA 4.0% w/v; dotted lines: media without BSA 4.0% w/v). 
Figure 4. Pareto charts for the estimated effects of the main factors and 2 level interactions of 
the analysis of a) %𝐴𝑚𝐵𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑𝑚𝑎𝑥 and 𝑘𝑟𝑒𝑙 from the sample and separate setup and b) the 
𝐴𝑈𝐶0−12ℎ from the continuous flow method. A factor was significant when the estimated effect 
(horizontal bars) was larger than the standardized effect (vertical line). 
Figure 5. AFM images to evaluate the effect of media components on Ambisome® liposomes. 
a) KRB BS 20.0 mM PL 4.0 mM, b) KRB BS 20.0 mM PL 4.0 mM BSA 4.0% w/v. The scale 
bar represents 200 nm. 
Figure 6. Observed and simulated (PBPK model) plasma concentration profiles of "liposomal 
AmB" and "released AmB" after the administration of Ambisome® to healthy subjects [25, 26]. 
Figure 7. Sensitivity analysis of PBPK model parameters on the "liposomal AmB" and 
"released AmB" 𝐴𝑈𝐶0−24ℎ obtained from simulated plasma concentrations in healthy subjects. 
The black line is the 𝐴𝑈𝐶0−24ℎ obtained from the validated PBPK model for healthy subjects. 
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Figure 8. 𝐴𝑈𝐶0−24ℎ calculated from simulated plasma concentration profiles with with the 
𝑘𝑟𝑒𝑙 from the in vitro release profiles against the 𝐴𝑈𝐶0−24ℎ obtained from the validated PBPK 
model for "liposomal AmB" and "released AmB". n = 5 subjects for each population. 
Figure 9. PBPK-PD model for a hypoalbuminaemic population (plasma protein fraction 0.5; 
healthy subjects: plasma protein fraction 1.0) –Simulated concentration and its 
pharmacodynamic effect on fungal cells. a) Simulated plasma concentration profiles of 
"liposomal AmB" and "released AmB" from the validated PBPK model for healthy subjects 
and the hypothesised model for the hypoalbuminaemic population, b) simulation of plasma 
concentrations following administration of a 300 mg dose of Ambisome®, c) simulated time 
killing rate coefficient (𝑘𝑘𝑖𝑙𝑙 ) (corresponding to the simulated plasma concentration profile of 
Figure 9b), and d) effect of the administration of Ambisome® on the growth of Candida 
albicans. 
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